CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR), the late-stage bio-scientific research and medical device company for early detection and treatment of reproductive-tract cancers, today announced the results of an exhaustive literature search that has validated the unique status of the P2X7 biomarker in scientific literature.
